RxDoctor Payments Data

Ian Villanueva

Family · Boulder, CONPI 1033706429

Payments from drug & device makers

$922in general payments, 2019–2025

Across 19 payments — averaging $48.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$162
  • Novo Nordisk$157
  • Bayer$149
  • Baxter Healthcare$118
  • Otsuka America Pharmaceutical, Inc.$87
  • Akebia Therapeutics Inc$81
  • plus $168 from 6 others

What the payments were for

  • Food & beverage$91599%
  • Education$71%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$922 in reported general payments places this provider in the 75th percentile of 2,182 family providers in Colorado.

See all family providers in Colorado

Medicare billing

Part B allowed, 2024
$48,682
Medicare patients
190
Services billed
807

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin29$14,886
Amlodipine Besylate114$911
Tamsulosin Hcl59$721
Lisinopril94$688
Atorvastatin Calcium82$581
Losartan Potassium61$537
Furosemide64$429
Allopurinol22$386
Hydralazine Hcl16$241
Metoprolol Succinate12$232
Hydrochlorothiazide46$222
Carvedilol19$169
Valsartan14$165
Calcitriol12$130
Simvastatin13$57

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$30$14,88629 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,182 family providers in Colorado.

Other family in Boulder

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →